Gal-3 Deficiency Suppresses
C57BL/6 mice
NLRP3
Novosphingobium aromaticivorans
galectin-3
galectin-3 inhibitor
primary biliary cholangitis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
06
2018
accepted:
22
05
2019
entrez:
25
6
2019
pubmed:
25
6
2019
medline:
11
11
2020
Statut:
epublish
Résumé
Gal-3 has the role in multiple inflammatory pathways. Multiple-hit etiology of primary biliary cholangitis (PBC) and evolving immune response at various stages of the disease includes involvement of Gal-3 in PBC pathogenesis. In this study we aimed to clarify the role of Gal-3 in
Identifiants
pubmed: 31231399
doi: 10.3389/fimmu.2019.01309
pmc: PMC6568238
doi:
Substances chimiques
Galectin 3
0
Inflammasomes
0
Interleukin-17
0
Lgals3 protein, mouse
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1309Références
Eur J Biochem. 2000 Mar;267(6):1837-46
pubmed: 10712617
Gastroenterology. 2002 Oct;123(4):1031-43
pubmed: 12360465
Liver Int. 2003 Apr;23(2):94-100
pubmed: 12654131
Hepatology. 2003 Nov;38(5):1250-7
pubmed: 14578864
Nature. 2005 Mar 24;434(7032):520-5
pubmed: 15791257
Nature. 2005 Mar 24;434(7032):525-9
pubmed: 15791258
Nature. 2005 Jun 2;435(7042):598-604
pubmed: 15931212
N Engl J Med. 2005 Sep 22;353(12):1261-73
pubmed: 16177252
Evid Based Complement Alternat Med. 2006 Mar;3(1):31-8; discussion 133-7
pubmed: 16550221
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Cell Host Microbe. 2008 May 15;3(5):304-15
pubmed: 18474357
J Immunol. 2008 Aug 15;181(4):2781-9
pubmed: 18684969
J Autoimmun. 2009 Feb;32(1):43-51
pubmed: 19101114
Hepatology. 2009 Mar;49(3):871-9
pubmed: 19185000
Hepatology. 2011 Apr;53(4):1270-81
pubmed: 21400555
Hepatology. 2012 Jun;55(6):1954-64
pubmed: 22213244
Immunol Res. 2012 Apr;52(1-2):100-10
pubmed: 22418727
Hepatology. 2014 Mar;59(3):898-910
pubmed: 23813842
Cytokine. 2013 Oct;64(1):172-80
pubmed: 23910013
PLoS One. 2013 Sep 10;8(9):e74225
pubmed: 24040208
PLoS One. 2013 Oct 09;8(10):e75361
pubmed: 24130706
J Mol Biol. 2014 Apr 3;426(7):1439-51
pubmed: 24326249
PLoS One. 2013 Dec 18;8(12):e83481
pubmed: 24367597
Hepatology. 2014 May;59(5):1944-53
pubmed: 24375552
Clin Cancer Res. 2014 Apr 1;20(7):1823-33
pubmed: 24526733
Hepatology. 2015 Feb;61(2):627-38
pubmed: 25042122
Hepatology. 2014 Nov;60(5):1708-16
pubmed: 25043065
Eur J Immunol. 2015 Feb;45(2):531-43
pubmed: 25359399
Cell Immunol. 2015 Mar;294(1):44-53
pubmed: 25684095
Mol Med. 2015 May 22;21:453-65
pubmed: 26018806
Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):387-400
pubmed: 26055245
Exp Biol Med (Maywood). 2015 Aug;240(8):1019-28
pubmed: 26142116
Medicine (Baltimore). 2015 Nov;94(44):e1888
pubmed: 26554784
Glycobiology. 2016 Jan;26(1):88-99
pubmed: 26646771
J Crohns Colitis. 2016 May;10(5):593-606
pubmed: 26786981
Sci Rep. 2016 Mar 21;6:23348
pubmed: 26996208
Stem Cells Int. 2016;2016:2640746
pubmed: 27057168
J Biol Chem. 2016 Jun 17;291(25):13318-34
pubmed: 27129206
FASEB J. 2016 Dec;30(12):4202-4213
pubmed: 27630169
J Hepatol. 2017 Feb;66(2):382-389
pubmed: 27720803
PLoS One. 2017 Feb 2;12(2):e0171005
pubmed: 28151995
Int J Mol Sci. 2018 Jan 26;19(2):null
pubmed: 29373564
Immunity. 1997 Dec;7(6):727-38
pubmed: 9430219
Hepatology. 1998 Sep;28(3):620-3
pubmed: 9731549